Mya Tran
@MyaPrecisionG
Followers
153
Following
1K
Media
24
Statuses
138
Precision Genomics Oncology Pharmacist, PharmD, BCOP, Indiana University Health - Simon Comprehensive Cancer Center
Indianapolis, IN
Joined February 2024
50 years.. and countless lives saved! Dr. Einhorn - we’re so grateful for you ♥️ #TesticularCancerCure #ResearchCureCancer @IUCancerCenter
2
1
22
Trends in target novelty in oncology research and development Most late-stage oncology drugs are not truly targeting novel biology. Although more than half of targets are novel at the preclinical stage, this proportion drops to roughly one third by phase III. What ultimately
2
23
68
📢 Big win for lung cancer screening in NY!!! Governor Hochul just signed bill S2000A into law which will now require insurance plans to fully cover lung cancer screening & any follow up diagnostic testing without copay — removing a major financial barrier to lifesaving care!!
4
15
51
A radiologist reached out: “So many of my patients will never know how much I think about them, gather second and third opinions about them, and ruminate about whether I've given them the best version of myself. I know I'll never meet them, but I hope they know how much I care.”
46
150
1K
It was truly an honor!!!#EndLungCancerNow. This wouldn’t been possible without the incredible support from Dr.Shields @drshieldsmd, Dr.Schneider @BryanPSchneider. More work ahead to further transform #PrecisionMedicine at IU but we’re making concrete progress 🧬🥂
So incredibly proud of my amazing & brilliant precision genomics specialist PharmD Dr. Mya Tran @MyaPrecisionG who was the recipient of the prestigious McHenry Sherman Lectureship award for End Lung Cancer Now. Dr. Tran has fundamentally transformed the genomic testing
0
1
8
Thank you @ConquerCancerFd for highlighting how important it is to change the stigma, nihilism, and culture surrounding a diagnosis of lung cancer. Anyone with lungs 🫁 can be diagnosed with lung cancer, and no one deserves lung cancer. Patients with #SCLC deserve MORE
@drshieldsmd reminds us of the stigma still present for people with small cell lung cancer and that it's time to change that. Her Conquer Cancer-funded research focuses on helping those with lung cancer by getting the right treatment to the right patient. #LungCancerAwareness
0
9
50
Such an important 🔑 initiative to provide the latest information for patients and their care partners impacted by #SCLC! In this session, we discuss everything related to antibody-drug conjugates (#ADCs) & their role in SCLC: 🧑🔬 MOA: biological chemo “missile” 🎯 Targets:
🎬 Exciting behind-the-scenes moment! Brittany recorded the Small Cell Lung Cancer Patient Education Program 2025–26 with Dr. @drshieldsmd today. This new video series will bring patients and caregivers the latest information about small cell lung cancer in an easy-to-understand
1
7
29
A true giant in the field of small cell lung cancer! An absolute honor to have Dr. Anish Thomas (@NIH) as a visiting professor at @IUCancerCenter, presenting his groundbreaking research with a “reverse translational” approach (patient bedside to the bench, and back!) on #SCLC.
1
9
31
🆙 #ESMO25 🇩🇪 🔥#LCSM Mini Oral, non mets ☑️LAURA MRD: NeXT Personal @PersonalisInc 🎯Osimertinib benefit mainteined regardless of post-CRT (randomisation) MRD status 🎙️ Dr. Edurne Arriola @OncoAlert @myESMO @Larvol #LiquidBiopsy
0
11
19
🆙#ESMO25🇩🇪 🔥#LCSM Educational Session ☑️Targeting oncogenes in NSCLC ☑️New targets 🎙️ Dr. Natasha Leighl @OncoAlert @myESMO @Larvol
0
24
72
Standing where I never thought I'd be 🧬🫁 I’m deeply grateful & humbled for this award Thank you to the selection committee & everyone who supported, mentored & believed in me-this wouldn't have been possible without you🙏🏼 @drshieldsmd @BryanPSchneider #PrecisionMedicine #ELCN
Join us Thursday, Nov. 13, 3:30–5 p.m. at Hine Hall Auditorium for the 3rd Annual McHenry-Sherman Scholarly Lecture celebrating the future of lung cancer research. Mya Tran, PharmD, BCOP, will present on genomics in precision medicine. Learn more: https://t.co/Pf4qSlR6U8.
0
2
12
Zipalertinib in EGFRex20ins NSCLC reported 31% of intracranial ORR 🧠. Today crowded space of TKI for EGFRex20ins. New SoC? Best sequence? Brain activity and toxicity relevant for 1st Line decision. #ESMO25
0
30
79
PHAROS: Encorafenib + binimetinib in BRAF V600E-mutant mNSCLC In treatment naive, median OS of ~4 years. Remarkable ❗️ ❔Differences in efficacy observed between first line (ORR 75%, PFS 30 months) vs 2nd line (ORR 49%, PFS 17 months) not observed in previous Dabrafenib +
1
17
44
🫁 #ESMO25 – BEAMION LUNG-1 w/ @DrSanjayPopat: first-line Zongertinib in HER2-mut NSCLC! 🎯ORR 77%, DCR 96% 💥Durable responses (6-mo DoR 80%, PFS 79%) 👍🏼 Manageable safety, no grade 4/5 AEs Promising data that gives HER2-mut NSCLC (quite literally) a new breath of LUNG ✨
1
15
37
Day 2 #ESMO25 Highlights: Breast Ca: 1. #DESTINYBreast11 NeoAdj TDXd 2. #DESTINYBreast05: TDXd in residual disease 3. #evERA: Giredestrant HR+ 4. #VIKTORIA1: Gedatolisib HR+ GU: 5. #KEYNOTE905: PeriOp EV + Pembro MIBC @myESMO #OncTwitter @OncoAlert @OncUpdates 1/13
2
26
49
Y’all. I seriously have the BEST team! You will truly not find a more amazing set of researchers, pharmacists, students, & physicians! A fierce group of dedicated, hard working, and brilliant investigators focused on uncovering the clinical, translational, and basic science
0
4
20
A lifelong dream came true today. Almost exactly 25 years ago today, I lost my strong Marine father to small cell lung cancer. Lost and broken into a million pieces, I sought out Dr. John Minna as a teenager to learn how I could become a translational thoracic oncologist to
15
20
192
Case series of tumor lysis syndrome with the bispecific T-cell engager tarlatamab in patients with small cell lung cancer @ClinicalLung. I have not seen this myself, but for various reasons, tarlatamab in #SCLC could be better with lower disease burden. https://t.co/lpMRTUnTX1
clinical-lung-cancer.com
Tarlatamab is a bispecific T-cell engager (BiTE) that binds delta-like ligand 3 (DLL3) on the surface of small cell lung cancer (SCLC) cells and the cluster of differentiation 3 (CD3) on cytotoxic...
3
28
63
Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer https://t.co/wrWagvQayh
3
20
116
Why is it important to look for germline/genetic mutations…? A list of associated cancers from @NCCN with common mutations one can find. #OncTwitter #MedEd #MedTwitter #lcsm #gism #gusm #bcsm
2
60
150